Virginia is currently home to 1822 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Breast Cancer
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Centra Health- Lynchburg General Hospital, Lynchburg, Virginia
Conditions: Heart Failure
Register for Updates
Nature IDEAS Study: an RCT to Increase Time Spent in Nature Among University Students
NCT06633367
Recruiting
This project will first examine nature opportunities, belonging and benefits with a multi-state nature-based intervention with a focus on students of color. In light of the syndemic, 'nature deficit disorder' and poor mental health, the investigators anticipate several far-reaching impacts that will (a) test a nationally useful standardized way to quantify exposure; (b) invest in nature resources and accessibility on campuses; and (c) promote the mental health and therapeutic benefits of nature... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
10/08/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Mental Health
Register for Updates
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05005728
Recruiting
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Open Versus Arthroscopic Stabilization of Shoulder Instability with Subcritical Bone Loss: the OASIS Trial
NCT04809064
Recruiting
This clinical trial will investigate the effects of three surgical procedures and the associated post-operative rehabilitation to optimize time to return to military duty, work and sports, and patient-reported physical function for military personnel and civilians with traumatic anterior shoulder instability and 10-20% glenoid bone loss.
Gender:
ALL
Ages:
Between 17 years and 50 years
Trial Updated:
10/08/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Shoulder Dislocation, Glenohumeral Dislocation, Anterior Shoulder Dislocation
Register for Updates
Treatment of Breast Fibroadenoma Targeted Tissue With HIFU
NCT03044054
Recruiting
This study evaluates the efficacy and the safety of the HIFU for the treatment of breast fibroadenoma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Virginia Health system, Charlottesville, Virginia
Conditions: Breast Fibroadenoma
Register for Updates
Recombinant VWF Concentrate and ECMO
NCT06118372
Recruiting
Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation. This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time. The primary objectives are t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: UVA Hospital, Charlottesville, Virginia
Conditions: Bleeding Disorder
Register for Updates
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
NCT05846516
Recruiting
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: * to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) * to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Pancreatic Ductal Adenocarcinoma
Register for Updates
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NCT04065438
Recruiting
This multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient has post-renal transplant recurren... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
10/07/2024
Locations: Children's Hospital of Richmond at VCU, Richmond, Virginia
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
A Web-Based Healthy Living Training for Promotores
NCT06627439
Recruiting
The goal of this clinical trial is to test a new web-based promotora de salud/ community health worker (CHW) training. This training is designed to provide CHWs with the knowledge and skills to effectively implement a healthy living intervention for Latinas. The main question it aims to answer is: o Do CHWs who complete the web-based healthy living training have higher self-efficacy in implementing core lifestyle intervention learning components for obesity interventions in Hispanics than CHWs... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: ISA Associates, Arlington, Virginia
Conditions: Obesity Prevention
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - 017-814-A, Arlington, Virginia
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Add-on Reparixin in Adult Patients With ARDS
NCT05496868
Recruiting
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Virginia Commonwealth University Health System, Richmond, Virginia
Conditions: Acute Respiratory Distress Syndrome, Adult
Register for Updates